Granulomatosis with polyangiitis (GPA) is an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAVs), characterized by granulomatous necrotizing vasculitis of small vessels [1]. Standard of care is based on a combination of glucocorticoids (GCs) and immunosuppressive agents [2]. For remission-induction of organ-threatening or life-threatening GPA, European League Against Rheumatism (EULAR) and French guidelines recommend the use of GCs in combination with either cyclophosphamide (CYC) or rituximab (RTX) [2,3].
